Transforming Prostate Cancer Care, Together

Stratify Prostate™ enables providers to order no-cost tumor sequencing for their patients with metastatic prostate cancer. By expanding access to NGS testing, we seek to accelerate enrollment of men with advanced prostate cancer onto precision oncology trials.

Today, we are targeting patient enrollment on studies evaluating the PARP inhibitor rucaparib in the TRITON2 and TRITON3 trials. As we gather more genomic data, our goal is also to catalyze new studies for patients harboring other targetable alterations.

Physicians interested in ordering tests for their patients should create a physician account.


Picture4.png

Expanding Access to Precision Oncology

By providing no-cost sequencing for 10,000 men with advanced prostate cancer, we are expanding access to tumor sequencing and precision medicine clinical trials.

Picture5.png

Accelerating Drug Development

We partner with drug developers to accelerate approval of new targeted therapies for men with advanced prostate cancer. 

Picture6.png

Advancing Scientific Discovery

Our collaborative network of leading physicians and researchers ensures insight we gain serves as a catalyst for scientific advances in prostate cancer.


StrataNGS™  - Tumor Sequencing Test

Web_stats.png

StrataNGS is a tumor sequencing test performed in Strata Oncology’s high-throughput CLIA-certified laboratory in Ann Arbor, MI. StrataNGS targets 87 genes by sequencing DNA and RNA from limited formalin-fixed paraffin-embedded tumor material. The test was designed to detect clinically actionable genetic variants for which there are associated approved therapies or clinical trials.

The StrataNGS test was based in part on the Strata team's prior development and validation of the Oncomine Cancer Panel (1), which was also the basis for the National Cancer Institute's MATCH assay (2).

1. Hovelson DH, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015 Apr;17(4):385-99
2. Lin CJ, et al. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017 Mar;19(2):313-327

How does Stratify Prostate work? 

Create an Account

Providers caring for men with metastatic prostate cancer in the United States can create a physician account to begin ordering StrataNGS tests immediately. Tumor sequencing is provided by Strata Oncology's CLIA laboratory using the StrataNGS Test, which reports on commonly mutated genes and associated clinical trials.

Order StrataNGS Test

 

Tests are ordered online by providers through our secure portal, and the patient's leftover tumor material is shipped to Strata Oncology for testing.  No payment or billing information is required. Test reports and potential clinical trial options are provided online to providers within 7-10 business days.  

Provider Resources

StrataNGS 'How to Order' Form

StrataNGS Test Overview & Technical Information 

Specimen Guidelines 

Provider FAQ

 

Stratify Prostate is made possible by providers who order the StrataNGS test as part of a minimal risk observational study – The Strata Trial (NCT03061305), sponsored by Strata Oncology. This study has been reviewed and approved by Chesapeake IRB.  The aim of the study is to better understand the frequency of tumor mutations in metastatic cancer and the utility of tumor genome testing in selecting treatments and clinical trials.  The study is conducted virtually and no patient interaction with study staff is required. In some cases, the study team may contact the provider to document treatment selection. 


Eric_small.jpg
Stratify Prostate is a unique opportunity to provide
our advanced prostate cancer patients access to
tumor sequencing at no cost...and accelerate
recruitment into precision oncology trials.
— Eric Small, MD, Deputy Director, UCSF Helen Diller Family Comprehensive Cancer Center; Chair, Stratify Prostate Executive Committee

Questions?

Call at or email